NO20044449L - Salter av tolterodin - Google Patents

Salter av tolterodin

Info

Publication number
NO20044449L
NO20044449L NO20044449A NO20044449A NO20044449L NO 20044449 L NO20044449 L NO 20044449L NO 20044449 A NO20044449 A NO 20044449A NO 20044449 A NO20044449 A NO 20044449A NO 20044449 L NO20044449 L NO 20044449L
Authority
NO
Norway
Prior art keywords
compounds
carbon atoms
tolterodine
relates
present
Prior art date
Application number
NO20044449A
Other languages
English (en)
Inventor
Walter Morozowich
Michael Hawley
Mark P Warchol
Satish Kumar Singh
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20044449L publication Critical patent/NO20044449L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse angår nye farmasøytisk aktive forbindelser, farmasøytiske preparater som inneholder det samme, forbindelsene for anvendelse som medikamenter, og anvendelsen av forbindelsene for fremstilling av spesifikke medikamenter. Foreliggende oppfinnelse angår også en metode for behandling som omfatter administrering av forbindelsene. Forbindelsene er spesielt farmasøytisk akseptable salter av tolterodin eller hydroksytolterodin, hvor saltet er av en syre valgt fra gruppen som består av allfatiske mono- og dikarboksylsyrer som omfatter fra 7 til 24 karbonatomer, alkandisulfonsyrer som omfatter fra 2 til 4 karbonatomer, naftalen-karboksylsyre-derivater som omfatter fra 1 I til 27 karbonatomer, maleinsyre og fumarsyre.
NO20044449A 2002-04-23 2004-10-19 Salter av tolterodin NO20044449L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/127,875 US7005449B2 (en) 2002-04-23 2002-04-23 Tolterodine salts
PCT/SE2003/000634 WO2003090734A1 (en) 2002-04-23 2003-04-22 Tolterodine salts

Publications (1)

Publication Number Publication Date
NO20044449L true NO20044449L (no) 2004-10-26

Family

ID=29215346

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044449A NO20044449L (no) 2002-04-23 2004-10-19 Salter av tolterodin

Country Status (25)

Country Link
US (1) US7005449B2 (no)
EP (1) EP1496882B1 (no)
JP (1) JP2005535578A (no)
KR (1) KR20040104585A (no)
CN (1) CN1646110A (no)
AP (1) AP2004003160A0 (no)
AT (1) ATE334665T1 (no)
AU (1) AU2003237724A1 (no)
BR (1) BR0309439A (no)
CA (1) CA2483092A1 (no)
DE (1) DE60307258T2 (no)
EA (1) EA200401108A1 (no)
EC (1) ECSP045373A (no)
ES (1) ES2266828T3 (no)
HR (1) HRP20040990A2 (no)
IL (1) IL164109A0 (no)
IS (1) IS7462A (no)
MA (1) MA27197A1 (no)
MX (1) MXPA04010472A (no)
NO (1) NO20044449L (no)
OA (1) OA12810A (no)
PL (1) PL371743A1 (no)
TN (1) TNSN04212A1 (no)
TW (1) TW200306802A (no)
WO (1) WO2003090734A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265680A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Oral liquid tolterodine composition
US7393874B2 (en) * 2003-04-08 2008-07-01 Hetero Drugs Limited Polymorphs of tolterodine tartrate
BRPI0409492A (pt) * 2003-04-18 2006-05-02 Pharmacia & Up John Company Ll terapias de combinação
JP5250205B2 (ja) * 2003-12-24 2013-07-31 シプラ・リミテッド トルテロジン、その組成物及び使用、及びその製造方法
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
ITMI20060110A1 (it) * 2006-01-24 2007-07-25 Dipharma Spa Procedimento per la purificazione di tolterodina
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
KR101188333B1 (ko) * 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
ITMI20082055A1 (it) * 2008-11-19 2009-02-18 Dipharma Francis Srl Procedimento per la preparazione di (r)-tolterodina base libera
MX2011011937A (es) * 2009-05-11 2012-01-27 Ratiopharm Gmbh Desfesoterodina en la forma de una sal del acido tartarico.
IT1396373B1 (it) * 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
IT1403094B1 (it) 2010-12-09 2013-10-04 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina o un suo sale
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
WO2020023910A1 (en) 2018-07-26 2020-01-30 Tolero Pharmaceuticals, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
CN111925294A (zh) * 2020-07-06 2020-11-13 济南大学 一种托特罗定帕莫酸盐及其制备方法
CN111728957B (zh) * 2020-07-06 2022-04-19 济南大学 一种托特罗定长效缓释微球及其制备方法
CN115814090B (zh) * 2022-11-22 2024-05-24 广州医科大学附属第一医院 烟草引发炎症的药物靶点
US12150922B1 (en) * 2023-12-08 2024-11-26 King Faisal University Methods of inhibiting cyclooxygenase (COX) using tolterodine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
PE20020547A1 (es) 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma

Also Published As

Publication number Publication date
ES2266828T3 (es) 2007-03-01
MXPA04010472A (es) 2005-07-14
US7005449B2 (en) 2006-02-28
MA27197A1 (fr) 2005-01-03
ATE334665T1 (de) 2006-08-15
CN1646110A (zh) 2005-07-27
IS7462A (is) 2004-09-20
HRP20040990A2 (en) 2004-12-31
KR20040104585A (ko) 2004-12-10
DE60307258T2 (de) 2007-10-25
EP1496882A1 (en) 2005-01-19
BR0309439A (pt) 2005-02-15
DE60307258D1 (de) 2006-09-14
IL164109A0 (en) 2005-12-18
TW200306802A (en) 2003-12-01
AP2004003160A0 (en) 2004-12-31
AU2003237724A1 (en) 2003-11-10
ECSP045373A (es) 2004-11-26
TNSN04212A1 (fr) 2007-03-12
EA200401108A1 (ru) 2005-06-30
PL371743A1 (en) 2005-06-27
OA12810A (en) 2006-07-11
EP1496882B1 (en) 2006-08-02
JP2005535578A (ja) 2005-11-24
CA2483092A1 (en) 2003-11-06
WO2003090734A1 (en) 2003-11-06
US20030199582A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
AP2004003160A0 (en) Tolterodine salts
WO2001019776A3 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
IL148103A0 (en) Novel dicarboxylic acid derivatives with pharmaceutical properties
WO2001019780A3 (de) Neuartige aminodicarbonsäurederivate mit pharmazeutischen eigenschaften
DK0661269T3 (da) Substituerede heterocykliske carboxylsyreamider, deres fremstilling og anvendelse som lægemidler.
WO2006034833A1 (en) Cyclic diarly ureas suitable as tyrosine kinase inhibitors
WO2002080899A1 (fr) Agent de traitement de maladie digestive
JP2005519073A (ja) 睡眠標的モジュレーターを使用する睡眠障害の治療
JPH0657685B2 (ja) ５α―リダクターゼ阻害活性を有するベンゾイルアミノフェノキシブタン酸誘導体、それらの製造方法およびそれらを含有する薬剤
ATE61340T1 (de) Aminosaeurederivate und deren verfahren zur herstellung.
HUT57763A (en) Process for producing 2,9-disubstituted-4h-pyrido(1,2-a)pyrimidine-4-one derivatives and pharmaceutical compositions comprising such compounds as active ingredient
EP1172107A4 (en) MEDICINES CONTAINING SULFOPYRANOSYLACYLGLYCEROL DERIVATIVES
US5506264A (en) Zinc tranexamate compounds
HU9800970D0 (en) Process for producing pharmaceutical compositions containing heptapeptide somatostatin derivatives of neurogene- and non-neurogene-antiflogistic and analgesic activity and peptidomimetica
WO2007105021A3 (en) Duloxetine salts
US6469064B2 (en) Materials and methods for the treatment of depression
CN113512025B (zh) 一种吲唑酯类化合物及其制药用途
AU2001255654A1 (en) Materials and methods for the treatment of depression
EA200000373A3 (ru) Новые соединения 1-аза-2-алкил-6-арилциклоалкана, способ их получения и содержащие их фармацевтические композиции
US20090298893A1 (en) Addition Salts of Tolperisone, Processes for Their Preparation and Use Thereof
NO20045223L (no) Orto-substituerte benzosyrederivater for behandling av insulinresistens
US7256191B2 (en) Materials and methods for the treatment of depression
US3903165A (en) Ethynylaryl amines and processes for their preparation
SI1501823T1 (sl) Novi piperidinil-alkilamino-piridazinonski derivati, postopek za njihovo pripravo in farmacevtski sestavki, ki vsebujejo te spojine
JP2006169176A (ja) 抗コロナウイルス活性を有するインドリル−ペンテン−ジオン誘導体

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application